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Abstract: The human immunodeficiency virus 1 (HIV-1) still remains one of the leading
life-threatening diseases in the world. The introduction of highly active antiretroviral therapy has
significantly reduced disease morbidity and mortality. However, most of the drugs have variable
penetrance into viral reservoir sites, including gut-associated lymphoid tissue (GALT). Being
the largest lymphoid organ, GALT plays a key role in early HIV infection and host–pathogen
interaction. Many different treatment options have been proposed to eradicate the virus from
GALT. However, it becomes difficult to deliver traditional drugs to the GALT because of its
complex physiology. In this regard, we developed a polymer-based Pluronic nanocarrier containing anti-HIV drug called efavirenz (EFV) targeting Microfold cells (M-cells) in the GALT.
M-cells are specialized epithelial cells that are predominantly present in the GALT. In this work,
we have exploited this paracellular transport property of M-cells for targeted delivery of Pluronic
nanocarrier tagged EFV, bioconjugated with anti-M-cell-specific antibodies to the GALT (nanodrug). Preliminary characterization showed that the nanodrug (EFV-F12-COOH) is of 140 nm
size with 0.3 polydispersion index, and the zeta potential of the particles was −19.38±2.2 mV.
Further, drug dissolution study has shown a significantly improved sustained release over
free drugs. Binding potential of nanodrug with M-cell was also confirmed with fluorescence
microscopy and in vitro uptake and release studies. The anti-HIV activity of the nanodrug was
also significantly higher compared to that of free drug. This novel formulation was able to
show sustained release of EFV and inhibit the HIV-1 infection in the GALT compared to the
free drug. The present study has potential for our in vivo targeted nanodrug delivery system by
combining traditional enteric-coated capsule technique via oral administration.
Keywords: HIV-1, drug delivery, GALT, M-cells

Introduction
The introduction of highly active antiretroviral therapy (HAART) has significantly
reduced human immunodeficiency virus (HIV) infection-related morbidity and mortality. However, a major limitation in this treatment is lifelong daily drug dosing regimens
and concomitant side effects.1,2 The gastrointestinal tract plays a key role in not only
early HIV infection in establishing viral reservoirs in gut-associated lymphoid tissue
(GALT) but also disease pathology.3 Moreover, most of the anti-HIV drugs have variable penetrance into viral reservoir organs such as central nervous system and GALT.
As a consequence, viral persistence remains an existing issue despite widespread
HAART usage.1,4–8 Many different treatment options have been proposed to eradicate
the virus from GALT. However, it has become increasingly difficult to design drugs
that would be targeted toward the GALT9 due to its complex physiology. Therefore,
the identification of the means to improve the bioavailability and therapeutic index of
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HAART drugs to eradicate the GALT reservoir is of great
importance. A targeted delivery is an ideal mean to reach the
GALT and remote lymphatic tissue where conventional drugs
have failed to reach due to its insolubility and inaccessibility
to lymph nodes. In this regard, microfold cells (M-cells) from
the small intestine are an excellent cellular target to deliver
anti-HIV drug to the GALT.
The epithelium that lines the human gut is impermeable to macromolecules/microorganisms except Peyer’s
patches, where the follicle-associated epithelium contains
M-cells. Many pathogenic organisms exploit M-cells
to cross the digestive epithelial barrier. 10 The M-cells
effectively bind, transport, and deliver macromolecules
to the cells underlying the mucosal immune system.
They mainly serve as antigen sampling cells that take
the foreign molecule from the gut and transport it to the
underlying lymphoid tissue. This unique characteristic
of M-cells has been utilized as a potential target for oral
vaccines.11,12 Since they possess a high transcytotic capacity to transport broad range of materials, M-cells have been
investigated for nanoparticle transport. However, possible
gastrointestinal digestion and poor intestinal absorption of nanoformulations leads to low bioavailability.13
Therefore, new oral formulations have to be developed
to tackle these difficulties. In this regard, one delivery
strategy can be designed to encapsulate the drug in some
drug carrier (liposome, Pluronic block copolymer micelles,
etc) to prevent the enzymatic digestion and facilitate the
M-cell-based uptake.
The objective of this study is to develop a long-acting
nanoformulated antiretroviral drug to improve the existing antiretroviral therapy. At our end, we have developed
a Pluronic nanocarrier with incorporated efavirenz (EFV)
drug. This formulation is further bioconjugated with a
universal M-cell-specific marker anti-glycoprotein 2 (GP2)
(together called nanodrug) to target it toward GALT.
Being one of the potent drugs preventing mother to child
transmission of HIV, EFV drug has been investigated for
pharmacokinetic variability, therapeutic effects, and toxicity among different patient populations.14–16 It has been
observed that a very strict pharmacological concentration is
a must in order to avoid virologic failure and tissue toxicity.
Therefore, it was worth investigating the nanoformulation
of EFV for anti-HIV activity and toxicity in GALT. An
in vitro model of M-cell co-culture system was used to
characterize this formulation for its cytotoxicity, drugloading capacity, sustained release, and anti-HIV activity.
In future, this nanoformulation will be encapsulated into
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an enteric coating capsule for in vivo drug delivery study
targeted to GALT.

Materials and methods
Materials
Pluronic F127 (F127), maleic anhydride, toluene,
pyridine, diethyl ether, N-(3-dimethylaminopropyl)-N′ethylcarbodiimide hydrochloride, pepsin, and high-performance liquid chromatography (HPLC) water were used as
received from Sigma-Aldrich Co. (St Louis, MO, USA). The
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt; MTS] was purchased from Promega Corporation
(Fitchburg, WI, USA). Transwell polycarbonated filter
plate with insert (24 well with pore diameter 0.4 µm) was
purchased from Corning Costar (New York, NY, USA). AntiGP2 antibodies were purchased from MBL (Nagoya, Japan).
Isotype antibodies were purchased from BD Biosciences
(San Jose, CA, USA). Human colon carcinoma Caco-2 cell
line (passages 20–30) and human Burkitt’s lymphoma Raji
B line (passages 30–40) were purchased from American
Type Culture Collection (ATCC) (Manassas, VA, USA) and
used within the passage mentioned in the parentheses. EFV
drug powder and all other chemicals were obtained from
Sigma-Aldrich Co.

Assay instruments and characterizations
Transmission electron microscopy (TEM) was used to determine the size and shape of the prepared F127COOH-EFV
micelles by Phillips CM-200 200 kV transmission electron
microscope at an accelerating voltage of 80 kV. A 90Plus Particle Size Analyzer (Brookhaven Instruments Corporation,
Holtsville, NY, USA) was used to measure the hydrodynamic
size and zeta potential of the F127COOH-EFV. A microplate
reader (Synergy HT, multi-mode microplate reader; BioTek,
Winooski, VT, USA) was used to measure the absorbance
of samples related to cell viability. A fluorescence spectroscopy technique based on a pyrene probe using a Shimadzu
spectrofluorometer (RF-5301PC; Shimadzu, Kyoto, Japan)
was applied to estimate the critical micelle concentration
(CMC) of the F127COOH micelles.

Methods

Synthesis of carboxylated functional Pluronic F127
(F127COOH)
As shown in Figure 1A, carboxylated ABA triblock copolymer F127 (F127COOH) was synthesized according to the literature with minor modification.17 Briefly, maleic anhydride
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Figure 1 (A) The illustration of synthetic routine of carboxyl-functionalized triblock copolymer F127 (F127COOH). (B) The efavirenz-loaded F127COOH micelles
bioconjugated with antibody.
Abbreviations: EO, ethylene oxide; PEO, polyethylene oxide; PO, propylene oxide; PPO, polypropylene oxide.

(1.93 g, 19.5 mmol) was added to a solution of F127 (25.0 g,
1.95 mM) in a mixed solvent of toluene (100 mL) and pyridine (5 mL). The whole mixture was stirred for 8 hours at
the room temperature (RT) under a nitrogen stream. After
purification by precipitation from excessive diethyl ether
thrice, 21.3 g (85%) of F127COOH as a light brown solid
was obtained.

Preparation of drug-loaded Pluronics with antibodies
conjugation (F127-COOH-EFV-GP2 or nanodrug)
In a typical experiment, hydrophobic drug of EFV dissolved
in chloroform (2.0 mg) was mixed with F127COOH in chloroform (20 mg) at a weight ratio of 1:10. The mixture was
gently stirred for 5 minutes, and a rotary vacuum evaporator with a water bath of 35°C was applied to evaporate the
organic solvent. The deposited film on the vials was hydrated
with 1.0 mL of HPLC water. The resulting clear dispersion
was kept at RT for further use.

International Journal of Nanomedicine 2015:10

The 200 µL of F127COOH-EFV aqueous solution
obtained in the previous step was incubated with 20 µL of
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride solution (1.92 mg/mL in water, 1.04×10‑6 mol) for
5–10 minutes, and then, 14 µL solution of anti-GP2 antibodies (0.5 mg/mL, 4.67×10‑11 mol) was added.18 After 1.5 hours
of incubation, the antibodies conjugated F127COOH-EFV
nanoparticles spun down at 10,000 rpm for 10 minutes and
then redispersed in 220 µL of phosphate-buffered saline
(PBS) for further application.

Transmission electron microscopy
The size of the F127COOH-EFV micelles was determined
using negative staining technique of TEM. In brief, one drop
of F127COOH-EFV micelles was spread on carbon support
film on 400 mesh Cu grids (type B; Ted Pella, Inc., Redding,
CA, USA). The grid samples were examined using TEM
imaging as explained earlier. The samples on the grids were
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negatively stained with phosphotungstic acid (2.0%, w/v;
pH 6.4) and dried at RT.

volume: 20 µL, detection wavelength: 215 nm, temperature
of performance: 30°C, retention time: 19.827 minutes).

Particle size and zeta potential

In vitro M-cell co-culture model

The hydrodynamic radius, size distribution, and surface
charge measurements of F127COOH-EFV were carried
out at 25°C using dynamic laser scattering (DLS) (90Plus
Particle Size Analyzer). Scattered light was detected
at a 90° angle and at a temperature of 25°C. Hydrodynamic size was expressed as mean ± SEM of triplicate
measurements. The aggregation stability of the nanoparticles in a 10 mM phosphate buffer was examined over
25 days.

The Caco-2 cells were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) (Thermo Fisher Scientific) with
20% (v/v) fetal bovine serum, and Raji cells were cultured
in RPMI 1640 medium supplemented with 10% (v/v) +1%
penicillin and streptomycin solution. The in vitro M-cell coculture model was adopted from previous studies.11,13 Briefly,
0.1 mL and 1.5 mL DMEM complete media were added to the
apical and basolateral sides of the 24-well Transwell plates,
respectively. The Caco-2 cells (5×105 cells/well) were seeded
on the apical sides of the Transwell, and the medium of the
apical side was changed every other day for next 14 days
of culture. Raji cells (3×105 cells/well) were suspended in
complete RPMI 1640/DMEM (1:2) mixture and then added
to the basolateral chamber of the Transwell; co-culture was
maintained for 12 days. The integrity of the epithelial barrier
was measured by transendothelial electrical resistance using
Millicell-ERS microelectrodes (EMD Millipore, Billerica,
MA, USA).20 Caco-2 cells were also cultured without Raji
cells to serve as a control.

Colloid and physiological stability
The nanocarriers were stored at 4°C, and the durability
of their structural integrity was evaluated by measuring
their size for up to 28 days. Further, their stability in blood
fluid was assessed by measuring their size in an in vitro
closed circulatory system at 37°C for up to 28 hours. This
closed circulation system was set up using a bidirectional,
self-priming peristaltic pump (Mini Pump Peristaltic Pump
Variable Flow C-2 Lab Pump; Thermo Fisher Scientific,
Waltham, MA, USA). The nanoformulation was allowed
to circulate in a 0.8 mm capillary 120 times at a flow rate
of 1 mL/min. The circulating medium was prepared with
5% dextran-500 (catalog no 50-247-495; Thermo Fisher
Scientific) in PBS, which gave a viscosity equivalent to
that of blood (4.5 cP). Samples were collected after 10, 30,
60, and 120 circulations and subjected to size analysis by
DLS.19

Dissolution of the nanoformulation
A 2 mL solution of F127COOH-EFV nanoparticles (0.5 mL,
concentration: 2 mg/20 mg ratio drug/F127COOH) was
placed into a dialysis bag (molecular cutoff: 6 kDa), sealed,
and put into a tube filled with 30 mL dissolution solution
(composition: 0.1% Tween 20 aqueous solution). The tube
was placed on a 37°C shaker at 150 rpm. At each time point
(0 minute, 5 minutes, 10 minutes, 15 minutes, 30 minutes,
60 minutes, 2 hours, 4 hours, 8 hours, 1 day, 2 days, 4 days,
6 days, 8 days, 10 days, 12 days, and 14 days), 100 µL of
solution was taken out from the tank when the drug was
releasing out of the dialysis bag and 100 µL of fresh dissolution was refilled. The same concentration of free drug
was used as a control.
At the last time point, the drug concentration was
determined by HPLC (150 mm ×4.6 mm column, injection
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Flow cytometry
M-cells or differentiated Caco-2 cells were scrapped out
of the Transwell culture and washed with PBS. M-cells
were further washed with flow-cytometry (fluorescenceactivated cell sorting [FACS]) buffer (PBS, 5%–10% fetal
bovine serum, 0.1% NaN3 [sodium azide]), probed with the
anti-GP2 antibodies (2 µg/mL), and incubated at RT for
20 minutes in the dark. Cells were then washed with the
FACS buffer to remove the unbound antibodies, fixed with
2% paraformaldehyde, and analyzed by FACS (Accuri C6;
BD Biosciences). Caco-2 and Raji cells were gated for GP2
based on the isotype gating on respective cells.

Immunofluorescence staining of M-cells
Caco-2 cells cultured on coverslip were added to Raji cells
seeded in Transwell culture plate. After the incubation, the
Caco-2 monolayer was washed several times with PBS and
fixed with 4% paraformaldehyde for 30 minutes at 4°C.
Further, the cells were washed with 0.1% Triton X-100 in
PBS for three times for 5 minutes each. Primary antibodies
(anti-GP2 antibodies 2.5 µg/mL) were added in PBS with
0.1% Triton X-100 for 1 hour. The cells were washed three
times with 0.1% Triton X-100 in PBS for 5 minutes. After
washing, secondary antibodies (Alexa Fluor 488 goat anti
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mouse antibodies; 10 µg/mL) were added and incubated at
RT for 45 minutes. Cells were washed again with 0.1% Triton
X-100 in PBS. Coverslips were mounted on the slides with
ProLong® Gold antifade reagent (Invitrogen, Carlsbad, CA,
USA) before proceeding for fluorescence microscopy. The
stained cells were examined using a fluorescent Axio Imager.
M2 microscope and AxioCam MRm camera set (Carl Zeiss
Meditec AG, Jena, Germany).

Nanomedicine-based anti-HIV drug delivery targeting M-cells

at 37°C. After the incubation, the absorbance at 490 nm was
measured using the BioTek plate reader (BioTek). Untreated
cells incubated with fresh media alone were considered as a
control. All measurements were taken eight times. The net
absorbance (A) was taken as an index of cell viability. The
cell viability was calculated as sample/control ×100%. The
nanoformulations that did not cause more than 10% loss in
cell viability after at least 24-hour exposure were considered
nontoxic.

Cellular uptake of fluorescent nanodrug
To examine the M-cell-mediated drug transport in the
in vitro system, a specially designed nanoformulation was
prepared. For this purpose, F127-COOH-EFV-GP2 was
further conjugated with fluorescent dye Alexa Fluor 610X
NHS (N-hydroxysuccinimide) ester (Invitrogen)21 before the
experiment. The uptake of fluorescent nanodrug (FND) by
M-cells was investigated using a fluorescence microscope
(Axio Imager 2; Carl Zeiss Meditec AG). The ethanol-treated
glass slides were put in six-well plates and coated with 0.01%
poly-l-lysine. The Caco-2 cells were seeded in these six-well
plates at the density of 5×105 cells/well and allowed to adhere
and grow. In one set of wells, Caco-2 cells were co-cultured
with Raji cells for 5–7 days to obtain M-cells, and other set
of cells were kept as control. At the end of the incubation,
cells were washed and supplemented with fresh media containing 0.07 mg/mL of nanodrug and incubated at 37°C for
2 hours. After the incubation, cells were washed with PBS
to remove any unabsorbed free nanodrug. Fluorescence was
measured in the lower (receiving) chamber from 0 hour to
48 hours in order to observe the FND transport via M-cells.
For the fluorescence imaging studies, the cells were fixed
with paraformaldehyde for 30 minutes and mounted on the
slide and images of M-cells with accumulated FND were
obtained as described above.

Cellular toxicity of nanodrug
Cytotoxicity of the nanoformulation was determined by using
MTS assay (G3582; Promega Corporation) on Caco-2 cells
and primary human macrophages. Briefly, cells were preincubated in 96-well plates with Caco-2 cells and then treated
with various concentrations of nanodrug (0.1–10 mg/mL) for
24 hours at 37°C. In case of primary human macrophages,
cells were exposed at the concentrations of 1–100 µg/mL of
nanodrug for 24 hours, separately. After the treatment, cells
were washed and incubated with fresh respective growth
medium. Cells were further incubated with 20 µL of MTS
reagent (CellTiter 96® AQueous One Solution; Promega,
Madison, WI, USA) in complete 100 µL cell media for 1 hour

International Journal of Nanomedicine 2015:10

Reactive oxygen species assay
The productions of reactive oxygen species (ROS) following exposure to different concentrations of nanodrug
(0.1–10 mg/mL) were detected in Caco-2 cells using dichlorofluorescein diacetate assay (Molecular Probes, Eugene,
OR, USA) as per previous published protocol.22 Cells were
cultured in 96-well plates (100,000 cells/well) overnight
to allow 70% confluence. The next day, cells were treated
with different concentrations of nanodrug for 24 hours as
mentioned above. The following day, cells were washed and
pretreated with antioxidant catalase (0.001 mg) for 2 hours.
Next, the cells were treated with dichlorofluorescein diacetate assay (100 µM) for 1 hour at 37°C and finally read in
a BioTek Synergy HT microplate reader (excitation 485 nm
and emission 528 nm; BioTek). Cells treated with H2O2
(50 µM) for 2 hours were considered as positive control.22

Anti-HIV activity of nanodrug
The nanodrug was further investigated for anti-HIV activity
in primary human macrophage and M-cell culture model,
respectively.
Primarily, human peripheral blood mononuclear cells
were isolated from healthy donor and differentiated to macrophages as per previously published protocol.23 Briefly,
peripheral blood mononuclear cells were isolated with
Ficoll-Hypaque (Pharmacia) gradient and cells were allowed
to differentiate for 7 days in the presence of human macrophage colony stimulating factor (Sigma-Aldrich Co.) to
macrophages. Following 7 days of incubation, macrophages
were infected with HIV-1BaL (National Institutes of Health
AIDS Research and Reference Reagent Program; Cat 510)
(100 ng) and incubated for 24 hours. The next day, cells were
thoroughly washed to get rid of any unattached virus particle
and fresh medium was added. At the same time, same concentration (70 µg/mL) of nanodrug and unformulated drug
(EFV) was added to these cells separately. The HIV-infected
macrophages served as control. The nanodrug/EFV drugtreated cells were monitored for up to 10 days along with
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infected control cells. The cell supernatant was collected at
days 0, 1, 3, 5, and 7 and 10 days post treatment. The viral
p24 level in the supernatant was measured with p24 ELISA
assay (Cat 0801200; ZeptoMetrix Corporation, Buffalo, NY,
USA). The minimum assay detection limit for p24 antigen
by ELISA was 7.8 pg/mL as provided by the manufacturer.
The p24 level at different time points gave the level of viral
inhibition with nanodrug and EFV. The p24 level of the culture supernatant was inversely proportional to the anti-HIV
activity of nanodrug.
Simultaneously, a parallel anti-HIV activity study was
set up in an in vitro model of M-cell. In this model, Raji cells
were exposed to HIV-1BaL at the concentration of 100 ng
for 24 hours in a co-culture and then washed from unattached viral particles.24,25 Following this, same concentration (70 µg/mL) of nanodrug and EFV was added to M-cell
culture model separately. The M-cell co-culture model
was observed for 10 days for viral replication, which was
measured by p24 ELISA assay (ZeptoMetrix Corporation)
at different time points up to 10 days. The untreated Raji
cells were kept as a control for all the experiments related
to drug activity. In the M-cell culture model, infected Raji
cells were also treated with EFV to compare with nanodrug.
The effect of nanodrug on HIV replication was measured
for up to 10 days post treatment in culture supernatant.
At the end of both the experiments, a quantitative HIV-1
DNA protocol (long terminal repeat [LTR] real-time polymerase chain reaction) was used to analyze the viral transcripts in HIV-infected Raji cells and macrophages. This was
done in order to ensure that untreated macrophages and Raji
cells got infected with the exposure of HIV-1. The following
previously published23 primers and probes were used: LTR
U5/R – sense-5′-GGCTAACTAGGGAACCCACTG-3′,
antisense-5′-CTGCTAGAGATTTTCCACACTGAC-3′,
and probe 5′-FAM-TGTGTGCCCGTCTGTTGTGTGTAMRA-3′. Relative gene expression was quantitated, and
the mean fold change in expression of the target gene was
calculated using the comparative CT method (transcript
accumulation index =2−ΔΔCT). All data were normalized
for quantity of RNA input by performing measurements on
an endogenous reference gene, GAPDH.

Statistical analysis
All experiments were performed in replicates, and data
are presented as mean ± SE. The statistical analysis was done
by two-tailed paired t-test with GraphPad Prism software
(GraphPad Software, Inc., La Jolla, CA, USA). A P-value
of 0.05 was considered as significant.
5824
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Results and discussion
Preparation and characterization of
nanodrug formulation
EFV is a non-nucleoside reverse transcriptase inhibitor being
used as part of HAART for the treatment of HIV-1 infection.
Although it is always given in combination with other drugs
to treat HIV infection, low efficacy is still a main concern
for this drug. This is due to its poor aqueous solubility, low
bioavailability, and resistance profile that may attenuate its
therapeutic effect.26
Currently, nanotechnology has attracted significant attentions in the field and also brought a revolutionary change
in the drug delivery system. By now, over 20 nanodrug
formulations have been approved by US Food and Drug
Administration (FDA).27 Among these nanomaterials, F127
plays an important role because of its specific chemical
structure and excellent biological biocompatible future.17
Figure 1A and B elucidated the main idea for the preparation
of F127COOH-EFV nanodrug formulation. The synthetic
yield of F127COOH from F127 was around 85%. The load
yield of EFV in F127COOH-EFV nanodrug formulation,
close to 100%, was determined by HPLC assay.
As shown in Figure 1A, Pluronics are block copolymers
that consist of hydrophilic polyethylene oxide (PEO) and
hydrophobic polypropylene oxide (PPO) blocks arranged in
a basic PEOx-PPOy-PEOx structure (where x and y represent the repeated number of times ethylene oxide [EO] and
propylene oxide [PO] in the structure, respectively). F127
can easily form as core/shell nanoparticles in the aqueous
solution by simple hydration technique, and its hydrophobic core can act as an accommodation for lipophilic drug.
In this spontaneously formed core–shell structure, poorly
soluble drugs can be incorporated into the hydrophobic
core and protected from inactivation in biological media,
and the outside, hydrophilic section layer may endow the
micellar system many advantages, such as increased drug
solubility, circumvented reticuloendothelial system uptake,
improved circulation time, and enhanced permeability and
retention effect.3 It has already been applied in the fields of
biomedicine, drug delivery systems, and gene therapy due to
its amphiphilic structure and high biocompatibility.28,29 F127
Pluronic (PEO101-PPO56-PEO101) (SP1049C) is now tested
in Phase III clinical investigation in patients with metastatic
adenocarcinoma of the esophagus, gastroesophageal junction,
and stomach. It has been reported to exhibit an acceptable
safety profile with a maximum tolerated dose of 70 mg/m2
with sustained drug release and clearance profile in comparison to conventional formulation.30,31

International Journal of Nanomedicine 2015:10

Dovepress

Nanomedicine-based anti-HIV drug delivery targeting M-cells

To improve the target efficiency, new type of F127 with
functional group is produced by surface chemical structure
modification. In our study, carboxyl groups were introduced
on the PEO terminal of F127 (the product of carboxylated
F127 is abbreviated as F127COOH) for the purpose of bioconjugation via gentle esterification with maleic anhydride.
By typical preparation process of micelles, EFV encapsulated
in carboxyl-functionalized amphiphilic polymers can result in
stable, micelle-like structures due to the strong hydrophobic
interactions between native hydrophobic EFV and the PPO
hydrocarbon chains (from hydrophobic section of F127) to
form F127COOH-EFV nanoparticles. Anti-GP2 antibodies
were conjugated with carboxyl groups on the surface of
F127 via the formation of active amino intermediate group
(Figure 1B). Being a very specific monoclonal antibody
designed for human M-cells, anti-GP2 antibody will help
in specific targeting of this nanodrug toward M-cell located
at the GALT.32,33
This work is a consequent study based on our previous
achievement on the F127COOH application.17 As we reported
before, the degree of maleic acid substitution onto F127
was ~1.5 mol%. The yield of F127COOH in this synthesis
was measured to be above 85% by acid–base titration, and
no significant degradation of the copolymer was found. The
CMC determined the stability of micelles against possible
dilution of the micellar system in bodily fluids. To this end,
the CMC of F127COOH nanoparticles was 4.7×10−7 M,
which indicates extreme stability after dilution. The size of
F127COOH-EFV nanodrug formulation in aqueous media
was around 140 nm with excellent monodispersion under
TEM measurement, shown in Figure 2A. The hydrodynamic
size in aqueous dispersion by method of DLS has high consistence with TEM results, which was around 140 nm with

0.12 polydispersion index (PDI). In general, the value of PDI
less than 0.3 is recognized as a narrow size distribution for
particles. The shape and the size were not significantly altered
after conjugation with anti-GP2 antibodies. The TEM analysis clearly indicated that no aggregation occurred during the
conjugation process. The surface charge of F127COOH-EFV
nanodrug formulation was 19.38±2.2 mV by zeta potential
measurement. Vectorization of the nanocarriers with antibodies did not affect the surface charge and had negligible
change in the particles.
DLS technique was also used to measure the hydrodynamic size distribution and colloidal stability of F127COOHEFV in PBS. As displayed in Figure 2B, the DLS results
showed the average hydrodynamic radius of F127COOHEFV to be 128.8±15.6 nm (PDI =0.10) over 2 weeks. The
surface charges of nanodrug formulation of F127COOH-EFV
were not significantly changed with or without conjugation
of antibodies based on the DLS measurements. The mimic
stability evaluation in blood fluid was also found to be
stable by measuring their size in an in vitro closed circulatory system at 37°C for up to 28 hours (viscosity: 4.5 cP).19
The time-dependent changes in hydrodynamic diameter of
the F127COOH-EFV with conjugation of antibodies were
less than 10% under the PBS (pH 7.4) and 0.005% pepsin
solution (pH 6.8) (Figure 3A and B), indicating that these
nanoparticles have well colloidal stability for a quite long
term in a blood physiological condition and intestine enzymatic circumstance.
Generally, the stability test on nanodrug under gut circumstance is critical for the full understanding of the characterization and fate of particles applied in in vivo model
and potential clinic. In our strategy, this nanodrug will be
finally encapsulated into an enteric-coated capsule for oral
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Figure 2 (A) TEM and (B) DLS of the formulation.
Notes: (A) Presents the representative particle shape and size of F127COOH-EFV nanodrug around 120–140 nm using the TEM technique, which shows excellent
monodispersion directly. (B) Displays the hydrodynamic radius of F127COOH-EFV nanodrug particles in the aqueous solution about 130 nm using the DLS technique with
small size distribution index (PDI) as 0.10. The hydrodynamic size in aqueous dispersion by the method of DLS has high consistency with the TEM results.
Abbreviations: DLS, dynamic laser scattering; EFV, efavirenz; PDI, polydispersion index; TEM, transmission electron microscopy.
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Figure 3 Stability characterization of nanoformulation: (A) pH 7.4 PBS and (B) 0.005% pepsin solution.
Notes: (A) DLS hydrodynamic size against time indicated the long-term stability of nanodrug in aqueous solution. Both of them showed size fluctuation 10%. Hydrodynamic
diameter of F127COOH-EFV presented size fluctuation 10%, indicating the long-term well colloidal stability in a physiological condition (pH 7.4). (B) One week incubation
with 0.005% pepsin solution showed the stability of nanoformulation under intestine enzymatic circumstance.
Abbreviations: DLS, dynamic laser scattering; EFV, efavirenz; PBS, phosphate-buffered saline.

Sustained drug release of nanodrug
To analyze the drug release profile, F127COOH-EFV was
subjected to dissolution test. In complying with sink condition from FDA requirement on drug product dissolution,
F127COOH-EFV in PBS (pH 7.4) was placed in the dialysis
bag using composition of 0.1% Tween 20 aqueous solution
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as dissolution solution at 37°C.34 The released drug outside
of dialysis bag was sampled at different time intervals (from
5 minutes up to 14 days) and was assayed by HPLC.35
The data indicated that 80% of drug was released from
the Pluronic particles over 6 days. As shown in Figure 4,
the t1/2 of EFV in F127COOH-EFV nanodrug formulation
was about 48 hours (t1/2=48 hours). This was considerably
longer than the release of free drug (t1/2=8 hours). This
phenomenon presents the acceptable characterization for
sustained drug release in in vitro and may satisfy work in
in vivo. The free EFV without dialysis bag was also used as
second control, which provided t1/2=0 hour under the same
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administration in animals. This enteric surface coatings
can endow capsule presenting stability at highly acidic pH
(eg, in stomach) and breaks down rapidly at around pH 6.8
(eg, in intestine) to release drug. This is the main reason
why the stability test and drug release measurement are
not conducted under acidic condition in our experiment for
nanodrug.
In order to find out hydrodynamic size variation of
F127COOH-EFV nanodrug under mimetic intestine solution
(0.005% pepsin solution, pH 6.8), DLS size of particles was
monitored against time up to 7 days. The results showed
that fluctuation in diameter of particles was less than 10%
in 7 days, which is almost same as the variation extent in
water (Figure 3B). This 1-week measurement confirmed
the stability of nanoformulation under intestine enzymatic
circumstance.
Since drug release from nanoformulation follows diffusion mechanism, with intact shape and structure under
intestine enzymatic circumstance, the loaded EFV may
release at the targeted site and time once the nanoformulation
is encapsulated into enteric-coated capsule and administered
into mice. All these parameters, including drug pharmacokinetic and distribution, will be performed in future in vivo
studies.




)UHHGUXJZLWKRXWGLDO\VLVEDJ
)UHHGUXJZLWKGLDO\VLVEDJ
3RO\PHULFQDQRGUXJZLWKGLDO\VLVEDJ




















7LPH GD\V
Figure 4 Dissolution study of nanodrug in PBS in in vitro model.
Notes: Dispersion of the micelles in PBS (pH 7.4) placed in the dialysis bag and
dialyzed against the respective buffer solution at 37°C. The released drug outside of
dialysis bag was sampled at different time intervals (from 5 minutes up to 14 days)
and measured by HPLC. The data were expressed as 80% of drug released from the
Pluronics relative to the initial drug loading.
Abbreviations: HPLC, high-performance liquid chromatography; PBS, phosphatebuffered saline.
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dissolution condition. The delayed release of free drugs in
dialysis bag may come from the retardation effect of tight
composition in the cellulose structure.35 In vitro release of
drug from polymeric micelles was measured by the dialysis
bag diffusion technique.36 According to US pharmacopeia,
phosphate buffer (pH 7.4) containing 0.5% Tween 80 was
used as a dissolution medium. This dialysis-based in vitro
release assays under sink condition have been commonly
applied to assess the retention properties of encapsulated
drugs. However, these results are not always indicative of
the formulations’ actual in vivo behavior. There are two
mechanisms for the drug release delay: one is caused by
sustained drug release from the reservoir effect in polymeric
vehicles, which may attenuate with time and another retention
effect may come from the dialysis bag itself. It is reported
that the dialysis bag may limit the in vitro drug release.37
Although there is a drug release delay and about 15% of
drug remained in the dialysis bag from this in vitro method,
this dose decrease will not affect the administrated drug for
the future in vitro and in vivo application. Even considering
this delay impact from dialysis bag, the dissolution profile
for our Pluronic nanodrug formulation is still adequate for
sustained drug release requirement.

Cytotoxicity of nanodrug
The present study investigated a potential of nanodrug as
the M-cell-specific drug delivery vehicle for the GALT.
Lymphatic uptake of nanoparticle, retention, and sustained
release of the drug at the GALT depend mainly on the size,
shape, and surface characterization of the nanoparticle.
Generally, smaller particles have better lymphatic uptake
than larger particles with lower retention capability.2,38–40

It was also important to test whether the current nanodrug
itself causes oxidative stress to the cellular environment after
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Effect of nanodrug on ROS production
in Caco-2 cells
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In this regard, steric stabilization with hydrophilic polymer
like F127COOH can improve the uptake of EFV by lymph
nodes and increase their stabilization inside them. Lymph
node retention of micellar drug has been investigated by
other researchers in cancer therapy.41 However, it had limited
success due to poor loading capacity and toxicity issue.42
In order to address this issue, we carried out cytotoxicity
studies of this nanodrug (Figure 5).
In this regard, MTS assay was performed to evaluate the
cytotoxicity of nanodrug in Caco-2 cells and primary human
macrophages, respectively, as per published protocol.43 The
result indicated that nanodrug did not significantly affect the
cell viability over 24 hours incubation with Caco-2 cells at
nanodrug concentration of 0.1–10 mg/mL (Figure 5A). Even
in case of primary human macrophage, the effect of nanodrug on cell viability did not decrease significantly up to the
concentration of 100 µg/mL (Figure 5B). Both observations
indicated that there was no immediate cellular toxicity of
nanodrug on human cell line (Caco-2) and primary human
cells (macrophages) at the tested concentrations. Taking into
account the high drug-loading capacity and cellular toxicity, high drug concentrations (above 10 mg/mL) were not
considered for further evaluations. Along the same line, the
ratio of drug and polymer was also optimized in Caco-2 and
Raji cells in order to get the maximum drug activity (data
not shown). As a result, 0.07 mg/mL of nanodrug was used
for further in vitro characterization.
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Figure 5 Cytotoxicity of nanodrug on Caco-2 cells and primary human macrophages.
Notes: (A) Caco-2 cells were exposed to 0.1–10 mg/mL concentration of nanodrug for 24 hours. (B) Primary human macrophages were exposed to 1–100 µg/mL
concentration of nanodrug for 24 hours. After incubation, MTS assay was performed and optical density of culture supernatant was measured at 490 nm. Data were
presented as % survival of cells at different concentrations of nanodrug. Untreated cells were considered as control (0) with 100% viability. The changes in viability at different
concentrations of nanodrug compared to control were found to be nonsignificant.
Abbreviation: MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium.
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treatment, which may affect cellular metabolism. In this
regard, cells were treated with different concentrations of
nanodrug in order to observe the effect of this formulation on
ROS production. As explained in Figure 6, the current nanodrug did not induce any significant ROS production with the
treatment as high as 10 mg/mL. This observation indicated
that the current formulation did not cause any oxidative stress
to Caco-2 cells post treatment. Thus, it further assured the
nontoxicity of the nanodrug for cellular treatment.

Characterization of M-cells in co-culture
model
In the co-culture model, Caco-2 cells developed M-cellslike morphology after incubation with Raji cells. In order to
investigate the transformation of Caco-2 cells to M-cells, a
flow-cytometry analysis was done with M-cell-specific antiGP2 antibodies.44,45 Monoculture of Caco-2 cells was used for
this study as a negative control. The data indicated that 14%
of the Caco-2 cells developed M-cells-like characteristics
upon co-culturing with Raji cells (Figure 7), whereas there
was no M-cell characters observed in monoculture of Caco-2
cells. Thus, the transformations of M-cells from Caco-2 cells
were clearly observed through this analysis.
In order to confirm this observation, further characterization of M-cells was done through immunocytochemistry with
anti-GP2 antibodies. The cells were grown and co-cultured
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Figure 6 Effect of nanodrug on ROS production in Caco-2 cells.
Notes: Cells were exposed to 0.1–10 mg/mL concentration of nanodrug for
24 hours. At the end of incubation, ROS assay was performed. The fluorescence was
detected at 485 nm excitation and at 528 nm emission spectra. Catalase was used
as antioxidant control, and H2O2 was used as positive control. Data are expressed
as mean ± SE of RFU values of four independent experiments. A value of P0.0001
was indicative of significance (****). There was no statistical significance between
treated groups and control.
Abbreviations: ROS, reactive oxygen species; RFU, relative fluorescence unit; SE,
standard error.
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as mentioned above, and at the end of incubation, cells were
stained with anti-GP2 antibodies. The fluorescent image
analysis indicated that the presence of anti-GP2 antibodies
was significantly higher in M-cells compared to Caco-2 cells
alone as explained in Figure 8.

Assessment of model functionality
by FND transport
In order to monitor the functional activity of M-cell in in vitro
model, a transport study of Alexa Fluor 610X NHS esterconjugated nanodrug or FND was designed and monitored
the transport rate in mono (Caco-2) and co-culture (M-Cell)
models. These FND formulations were further conjugated
with anti-GP2 antibodies (FND-GP2). FND and FND-GP2
were added apically and incubated for 2 hours at 37°C. After
the incubation, parts of the Transwells were used for fluorescent microscopy studies to observe FND accumulation and
a parallel set of Transwells was kept to monitor the FND
transport from apical to basolateral site. The microscopic
analysis indicated that FND-GP2 was more accumulated in
the M-cells, at a greater extent, than FND. At the same time,
the Caco-2 cells treated with FND and FND-GP2 accumulated
significantly less fluorescence than the M-cells (Figure 9A).
Noteworthy, both M-cells and Caco-2 cells showed a
sustained uptake of FND in the external medium. The measurement of FND uptake on the basolateral side of Transwell
was done by measuring fluorescence. The nanodrug uptake
was measured in terms of fluorescence with respect to time
up to 48 hours. Along with higher accumulation levels,
the prolonged drug release characteristics from M-cells
were demonstrated compared to Caco-2 cells, indicating the
superior role of M-cells for drug delivery (Figure 9B). We
hypothesized that Pluronic micelles were transported out
of the cells through recycling trafficking of endosomes as
reported previously.46

Anti-HIV activity of nanodrug
Anti-HIV activity of nanodrug against HIV was tested in
primary human macrophages and in vitro M-cell model.
Primarily, human macrophages were infected with HIV-1 for
24 hours and then treated with nanodrug or EFV separately.
Nanodrug treatment data indicated that there was consistent
viral inhibition up to day 10 and beyond, whereas free EFVtreated cells showed immediate inhibition of viral replication
on day 1 and following that there was an increase in viral
p24 level, indicating gradual loss in antiviral activity of EFV.
At the end of the experiment (day 10), the effect of EFV
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Figure 7 Flow cytometric analysis of M-cell-like characteristics in Caco-2 and Raji cell co-culture systems.
Notes: Caco-2, Raji, and Caco-2 + Raji cells were cultured simultaneously and stained with anti-GP2 antibody at the end of incubation. Cells were gated for GP2, based on
the isotype in the respective cells.
Abbreviations: FITC, fluorescein isothiocyanate; GP2, glycoprotein 2.
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Figure 8 Immunocytochemical analysis of M-cell characters in Caco-2 and Raji co-culture.
Notes: Cells were exposed to anti-GP2 antibody after differentiation process and stained with fluorescent secondary antibody. Microscopic images were taken through Axio
Imager 2. DAPI (in blue) indicated the cell nucleus, and the cells those have developed M-cell-like characteristics were stained with GP2 antibody (green).
Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; GP2, glycoprotein 2.

treatment significantly decreased and p24 level increased
up to the level of untreated cells. In this regard, untreated
and HIV-1-infected macrophages were served as a positive
control, which showed gradual increase in the p24 level up
to day 10, indicating unaffected HIV-1 replication in macrophages (Figure 10A).
In order to observe anti-HIV activity of nanodrug in
M-cell model, Raji cells were infected with HIV and cultured
with Caco-2 cells. They were further treated separately with
nanodrug or EFV for up to 10 days at the same concentration.
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Viral p24 protein level was measured in culture supernatant
at different time points. In the case of nanodrug, p24 protein
level did not change up to day 2. However, from day 3 to
day 10, there was a significant decrease in viral replication
when compared to EFV-treated cells. Compared to nanodrug, EFV treatment resulted in an immediate reduction in
viral replication, but p24 level increased closer to the level
of untreated cells within day 10, indicating viral rebound in
the cells (Figure 10B). As a positive control, p24 level of
HIV-infected Raji cells was observed up to day 10.
International Journal of Nanomedicine 2015:10
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Figure 9 Uptake and release of fluorescent dye (Alexa Fluor 610X NHS ester) labeled nanodrug (FND) by M-cells.
Notes: (A) Uptake of anti-GP2-conjugated nanodrug by M-cells within 2 hours of incubation. Caco-2 and M-cells were treated with and without antibody (GP2) tagged with
FND. The treatments were as follows (from left to right): (1) Caco-2 cells treated with FND; (2) Caco-2 cells treated with FND + GP2; (3) M-cells treated with only FND;
and (4) M-cells treated with FND + GP2. Cells were stained with DAPI in order to observe the localization of FND and are represented in the following order: (a) FND;
(b) DAPI; and (c) FND and DAPI merged (scale bar 50 µm). Co-localization of FND on the cell surface is shown as a magnified image in (I), (II), and (III) of A (scale
bar =20 µm). (B) Release of FND in vitro Transwell co-culture model at lower chamber. Drug release was observed with respect to fluorescence measurement. Fluorescent
drug release was significantly sustained in M-cells than Caco-2 cells (P0.0015).
Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; FND, fluorescent nanodrug; GP2, glycoprotein 2; NHS, N-hydroxysuccinimide.

At the end of two experiments, the primary infection
of HIV-1BaL in both Raji and macrophages was confirmed
by HIV-LTR-R/U5 gene polymerase chain reaction. The
data represented in transcript accumulation index values in
both cells indicated that both cell types were successfully
infected with HIV and presented an optimum challenge
to test the nanodrug in evaluating its anti-HIV activity
(Figure 10C).
International Journal of Nanomedicine 2015:10

The epithelium layer that lies in the gut is impermeable
to any macromolecules, including drug molecules except
Peyer’s patches that contain M-cells.11,13 In this study, we
have adopted an in vitro culture system that reproduced the
characteristic of M-cells. Since this in vitro model is the
only tool to study the human M-cells, it was very important
to characterize it in detail. The biological characterization
revealed that the presence of Raji cells in co-culture with
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Figure 10 Comparative analysis of anti-HIV activity of nanodrug vs unformulated EFV on macrophages and M-cells.
Notes: (A) Effect of nanodrug on HIV-infected macrophages compared to EFV. (B) Effect of nanodrug or EFV was observed on HIV replication in M-cell culture model. HIV
replication was monitored with respect to p24 protein level in the culture supernatant at different times (days). The data represented with respect to p24 level vs time (days)
in untreated, nanodrug-treated (ND, in green), and EFV drug-treated (FD, in red) M-cells exposed to HIV (P=0.001). Untreated and HIV-infected macrophage/Raji cells were
treated as positive control (in blue). Statistical significance was calculated with respect to P-values (P=0.001). (C) HIV-LTR-R/U5 gene expression was done through PCR.
The two columns show HIV infection in the Raji (black) and macrophage (gray) cells after 10 days of incubation. The LTR gene expressions in both cells were expressed in
TAI and normalized with housekeeping gene GAPDH.
Abbreviations: D, day; EFV, efavirenz; HIV, human immunodeficiency virus; LTR, long terminal repeat; PCR, polymerase chain reaction; TAI, transcript accumulation index.

monolayer of Caco-2 cells help the Caco-2 cells develop
M-cell-like characteristics. In order to confirm this, flow
cytometric analysis was done with Caco-2 cells and
Caco-2 + Raji cells co-culture, respectively. The analysis
indicated that there was a significant change in Caco-2 cell
surface, which is more close to M-cells. These data were
also corroborated with other immunocytochemistry analysis
indicating the co-cultured cells have expressed M-cellspecific characteristics confirming establishment of the in
vitro M-cell model. In order to observe the functional activity
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of the M-cell, anti-GP2-conjugated FND was introduced
in the M-cell model. Further, M-cell-mediated uptake and
release study was performed to observe the uptake and successive release of nanodrug. The initial immunofluorescence
study indicated that FND was taken up within first 2 hours
of incubation. FND + GP2 showed higher uptake, indicating the M-cell-specific binding of anti-GP2 antibodies and
adsorption of nanodrug. The absorption of FND and transport
of FND by M-cells were observed at the lower chamber
over a period of 48 hours. The fluorescence release study
International Journal of Nanomedicine 2015:10
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clearly indicated that these cells provided sustained release
of nanodrug that was slower than that of the unformulated
drug. We believe that the mechanism of accumulation and
release of unformulated drug and nanoformulated drug may
be different. In particular, nanoparticles should enter by
endocytosis-mediated transport and release through recycling
mechanism that is a slow process compared to trafficking of
the free low-molecular drug. This sustained release process
of nanodrug may be more therapeutically effective than that
of the unformulated drug.
Overall, the data clearly indicate the potentials of M-cell
to carry anti-HIV drug from the gut side to the GALT side.
In this regard, the binding of anti-GP2 antibodies may
improve targeting of drug molecules toward M-cell, and
following that, inherent transmigration capability of M-cell
takes the drug molecule to the other side of the barrier. The
anti-HIV activity data indicated that treatment of cells with
free drug or nanodrug significantly lowered levels of viral
replication compared to untreated Raji cells. In case of free
EFV, there was an immediate decrease in viral replication
as expected. However, rebound of viral p24 level within
day 10 indicated failure of sustained inhibition of HIV
replication in in vitro model. Whereas, in case of nanodrug,
the immediate response was slower, but the subsequent
sustained inhibition of viral replication was observed with
consistent decline in p24 viral protein even on day 10 post
infection. This observation definitely established the fact of
the unique nests of the F127COOH nanoformulation over
free EFV drug.
Nonetheless, the present study also acknowledged the
fact that macrophage or reticuloendothelial system can identify and clear the foreign substances or current nanodrug
in both the blood and tissues. This is an important part of
immune system that may bring obstacles for a nanoformulation directly applying in intravenous injection. However,
the experimental design for current in vitro and future
in vivo studies combines traditional oral drug formula with
nano-technique in which nanoparticle may escape from
macrophage tracking because of enteric coating capsule
employed in our study. The nanodrug will be first encapsulated into an enteric coating capsule and administrated
to mice. The present in vitro data verified the stability of
nanoparticles under mimic intestine circumstance. Since
the short period of drug release from nanodrug to the step
of uptake by intestinal epithelium, this antibody digestion
issue may be alleviated by our nanoformulation of enteric
coating capsule. Because enteric capsule has the character of pH sensitivity, the nanoformulation will come out
from cracked enteric capsule only at the intestine site and
International Journal of Nanomedicine 2015:10
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achieve the targeted drug delivery to increase therapeutic
efficacy.
Therefore, we report the transmigration of anti-HIV drug
molecule through M-cells, its potential release, and anti-HIV
activity. This study will also serve as a model for future
anti-HIV drug study with new formulations targeting toward
GALT. In the recent years, few studies indicated the potential of M-cell for vaccine delivery and also its role in HIV
transcytosis in the GALT.47 However, this is the first report
of using M-cells for anti-HIV drug delivery to the GALT and
high-efficiency targeted drug delivery system. Nonetheless,
the study could not establish the detailed nanodrug release
profile compared to free drug and long-term stability of the
drug in in vivo GALT model. Considering the limitations, the
study still could establish evidence of delivery of nanodrug
through M-cells, which is more therapeutically effective.
Most importantly, this may also reduce the viral reservoir
in the GALT compared to unformulated drug recommended
at the clinic.

Conclusion
The main property of M-cells is the vertical translocation of particle from the intestine to lymphoid system. By
utilizing this system, we have demonstrated the strong
potential of F127COOH-EFV formulation to be used for
high-efficiency targeted drug delivery system to the GALT.
We also observed the steady release of nanodrug in the cell
culture media compared to free drug. Considering the importance of GALT in HIV pathogenesis, this study will help
us to significantly reduce the viral load of the GALT and
improve the treatment outcome. It should now be possible
to identify the mechanism of M-cell-based drug transport
from the intestinal side to the GALT. The present study
will help to design future oral nanodrug system to deliver
anti-HIV drug with enteric-coated capsule that will survive
the acidic digestion of stomach and deliver the drug directly
to the GALT.
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